Browse OPRK1

Summary
SymbolOPRK1
Nameopioid receptor, kappa 1
Aliases KOR; OPRK; K-OR-1; KOR-1; Opiate receptor, kappa-1; kappa opioid receptor; Kappa-type opioid receptor
Chromosomal Location8q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein
Domain PF00001 7 transmembrane receptor (rhodopsin family)
Function

G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain. Plays a role in mediating reduced physical activity upon treatment with synthetic opioids. Plays a role in the regulation of salivation in response to synthetic opioids. May play a role in arousal and regulation of autonomic and neuroendocrine functions.

> Gene Ontology
 
Biological Process GO:0002237 response to molecule of bacterial origin
GO:0006091 generation of precursor metabolites and energy
GO:0006813 potassium ion transport
GO:0007187 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger
GO:0007188 adenylate cyclase-modulating G-protein coupled receptor signaling pathway
GO:0007193 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway
GO:0007200 phospholipase C-activating G-protein coupled receptor signaling pathway
GO:0007218 neuropeptide signaling pathway
GO:0007586 digestion
GO:0007589 body fluid secretion
GO:0007611 learning or memory
GO:0007612 learning
GO:0007626 locomotory behavior
GO:0007631 feeding behavior
GO:0008306 associative learning
GO:0009060 aerobic respiration
GO:0009314 response to radiation
GO:0009615 response to virus
GO:0009914 hormone transport
GO:0010817 regulation of hormone levels
GO:0010959 regulation of metal ion transport
GO:0014046 dopamine secretion
GO:0014059 regulation of dopamine secretion
GO:0014072 response to isoquinoline alkaloid
GO:0015672 monovalent inorganic cation transport
GO:0015837 amine transport
GO:0015844 monoamine transport
GO:0015850 organic hydroxy compound transport
GO:0015872 dopamine transport
GO:0015980 energy derivation by oxidation of organic compounds
GO:0019098 reproductive behavior
GO:0019233 sensory perception of pain
GO:0022600 digestive system process
GO:0023061 signal release
GO:0030534 adult behavior
GO:0031098 stress-activated protein kinase signaling cascade
GO:0031635 adenylate cyclase-inhibiting opioid receptor signaling pathway
GO:0031644 regulation of neurological system process
GO:0032274 gonadotropin secretion
GO:0032275 luteinizing hormone secretion
GO:0032276 regulation of gonadotropin secretion
GO:0032277 negative regulation of gonadotropin secretion
GO:0032496 response to lipopolysaccharide
GO:0032844 regulation of homeostatic process
GO:0032868 response to insulin
GO:0032872 regulation of stress-activated MAPK cascade
GO:0032874 positive regulation of stress-activated MAPK cascade
GO:0032941 secretion by tissue
GO:0033603 positive regulation of dopamine secretion
GO:0033605 positive regulation of catecholamine secretion
GO:0033684 regulation of luteinizing hormone secretion
GO:0033685 negative regulation of luteinizing hormone secretion
GO:0034762 regulation of transmembrane transport
GO:0034764 positive regulation of transmembrane transport
GO:0034765 regulation of ion transmembrane transport
GO:0034767 positive regulation of ion transmembrane transport
GO:0038003 opioid receptor signaling pathway
GO:0038066 p38MAPK cascade
GO:0040017 positive regulation of locomotion
GO:0042220 response to cocaine
GO:0042698 ovulation cycle
GO:0042711 maternal behavior
GO:0042755 eating behavior
GO:0043266 regulation of potassium ion transport
GO:0043268 positive regulation of potassium ion transport
GO:0043270 positive regulation of ion transport
GO:0043278 response to morphine
GO:0043279 response to alkaloid
GO:0043410 positive regulation of MAPK cascade
GO:0043434 response to peptide hormone
GO:0043457 regulation of cellular respiration
GO:0043467 regulation of generation of precursor metabolites and energy
GO:0043627 response to estrogen
GO:0044057 regulation of system process
GO:0044058 regulation of digestive system process
GO:0044060 regulation of endocrine process
GO:0044708 single-organism behavior
GO:0044849 estrous cycle
GO:0045333 cellular respiration
GO:0045471 response to ethanol
GO:0046541 saliva secretion
GO:0046877 regulation of saliva secretion
GO:0046879 hormone secretion
GO:0046883 regulation of hormone secretion
GO:0046888 negative regulation of hormone secretion
GO:0048148 behavioral response to cocaine
GO:0048511 rhythmic process
GO:0048871 multicellular organismal homeostasis
GO:0050432 catecholamine secretion
GO:0050433 regulation of catecholamine secretion
GO:0050878 regulation of body fluid levels
GO:0050886 endocrine process
GO:0050890 cognition
GO:0050951 sensory perception of temperature stimulus
GO:0051047 positive regulation of secretion
GO:0051048 negative regulation of secretion
GO:0051051 negative regulation of transport
GO:0051403 stress-activated MAPK cascade
GO:0051607 defense response to virus
GO:0051930 regulation of sensory perception of pain
GO:0051931 regulation of sensory perception
GO:0051937 catecholamine transport
GO:0051952 regulation of amine transport
GO:0051954 positive regulation of amine transport
GO:0060746 parental behavior
GO:0060986 endocrine hormone secretion
GO:0070302 regulation of stress-activated protein kinase signaling cascade
GO:0070304 positive regulation of stress-activated protein kinase signaling cascade
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071396 cellular response to lipid
GO:0071804 cellular potassium ion transport
GO:0071805 potassium ion transmembrane transport
GO:0097009 energy homeostasis
GO:0097305 response to alcohol
GO:0098542 defense response to other organism
GO:1900744 regulation of p38MAPK cascade
GO:1900745 positive regulation of p38MAPK cascade
GO:1901379 regulation of potassium ion transmembrane transport
GO:1901381 positive regulation of potassium ion transmembrane transport
GO:1901652 response to peptide
GO:1903531 negative regulation of secretion by cell
GO:1903532 positive regulation of secretion by cell
GO:1903715 regulation of aerobic respiration
GO:1903937 response to acrylamide
GO:1904062 regulation of cation transmembrane transport
GO:1904064 positive regulation of cation transmembrane transport
GO:1990708 conditioned place preference
GO:2000505 regulation of energy homeostasis
Molecular Function GO:0001653 peptide receptor activity
GO:0004985 opioid receptor activity
GO:0008528 G-protein coupled peptide receptor activity
GO:0033218 amide binding
GO:0038048 dynorphin receptor activity
GO:0042277 peptide binding
GO:0042923 neuropeptide binding
Cellular Component GO:0030424 axon
GO:0030425 dendrite
GO:0033267 axon part
GO:0043025 neuronal cell body
GO:0043204 perikaryon
GO:0043679 axon terminus
GO:0044297 cell body
GO:0044306 neuron projection terminus
> KEGG and Reactome Pathway
 
KEGG hsa04080 Neuroactive ligand-receptor interaction
Reactome R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolOPRK1
Nameopioid receptor, kappa 1
Aliases KOR; OPRK; K-OR-1; KOR-1; Opiate receptor, kappa-1; kappa opioid receptor; Kappa-type opioid receptor
Chromosomal Location8q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between OPRK1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolOPRK1
Nameopioid receptor, kappa 1
Aliases KOR; OPRK; K-OR-1; KOR-1; Opiate receptor, kappa-1; kappa opioid receptor; Kappa-type opioid receptor
Chromosomal Location8q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of OPRK1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.48; FDR: 0.04630 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolOPRK1
Nameopioid receptor, kappa 1
Aliases KOR; OPRK; K-OR-1; KOR-1; Opiate receptor, kappa-1; kappa opioid receptor; Kappa-type opioid receptor
Chromosomal Location8q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of OPRK1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.9970.151
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592.160.0472
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.4630.743
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.70.0114
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of OPRK1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.811.8-70.577
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.17.71.41
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolOPRK1
Nameopioid receptor, kappa 1
Aliases KOR; OPRK; K-OR-1; KOR-1; Opiate receptor, kappa-1; kappa opioid receptor; Kappa-type opioid receptor
Chromosomal Location8q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of OPRK1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolOPRK1
Nameopioid receptor, kappa 1
Aliases KOR; OPRK; K-OR-1; KOR-1; Opiate receptor, kappa-1; kappa opioid receptor; Kappa-type opioid receptor
Chromosomal Location8q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of OPRK1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by OPRK1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolOPRK1
Nameopioid receptor, kappa 1
Aliases KOR; OPRK; K-OR-1; KOR-1; Opiate receptor, kappa-1; kappa opioid receptor; Kappa-type opioid receptor
Chromosomal Location8q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of OPRK1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolOPRK1
Nameopioid receptor, kappa 1
Aliases KOR; OPRK; K-OR-1; KOR-1; Opiate receptor, kappa-1; kappa opioid receptor; Kappa-type opioid receptor
Chromosomal Location8q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of OPRK1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolOPRK1
Nameopioid receptor, kappa 1
Aliases KOR; OPRK; K-OR-1; KOR-1; Opiate receptor, kappa-1; kappa opioid receptor; Kappa-type opioid receptor
Chromosomal Location8q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between OPRK1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolOPRK1
Nameopioid receptor, kappa 1
Aliases KOR; OPRK; K-OR-1; KOR-1; Opiate receptor, kappa-1; kappa opioid receptor; Kappa-type opioid receptor
Chromosomal Location8q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting OPRK1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting OPRK1.
ID Name Drug Type Targets #Targets
DB00193TramadolSmall MoleculeCHRM3, GRIN3A, HTR2C, OPRD1, OPRK1, OPRM1, SLC6A2, SLC6A48
DB00295MorphineSmall MoleculeLY96, OPRD1, OPRK1, OPRM14
DB00318CodeineSmall MoleculeOPRD1, OPRK1, OPRM13
DB00321AmitriptylineSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, ......35
DB00327HydromorphoneSmall MoleculeOPRD1, OPRK1, OPRM13
DB00370MirtazapineSmall MoleculeADRA1A, ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2C, ADRB1, ADRB2, DRD1 ......23
DB00396ProgesteroneSmall MoleculeAR, CYP17A1, ESR1, NR1I2, NR3C1, NR3C2, OPRK1, ORM1, PGR, SHBG10
DB00454PethidineSmall MoleculeCES1, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, GRIN1, GRIN2A, GRIN2B, GR ......16
DB00497OxycodoneSmall MoleculeOPRD1, OPRK1, OPRM1, ORM1, ORM25
DB00514DextromethorphanSmall MoleculeCHRNA2, CHRNA3, CHRNA4, CHRNA7, CHRNB2, CHRNB4, CYBA, CYBB, GRIN3A ......21
DB00555LamotrigineSmall MoleculeADORA1, ADORA2A, ADRA1A, ADRA2A, ADRB1, CACNA1E, CHRM1, CHRM2, CHR ......44
DB00611ButorphanolSmall MoleculeOPRD1, OPRK1, OPRM13
DB00647DextropropoxypheneSmall MoleculeCES1, OPRD1, OPRK1, OPRM14
DB00652PentazocineSmall MoleculeOPRK1, OPRM1, SIGMAR13
DB00704NaltrexoneSmall MoleculeOPRD1, OPRK1, OPRM13
DB00708SufentanilSmall MoleculeOPRD1, OPRK1, OPRM13
DB00813FentanylSmall MoleculeOPRD1, OPRK1, OPRM13
DB00825MentholSmall MoleculeOPRK1, TRPA1, TRPM8, TRPV34
DB00836LoperamideSmall MoleculeCACNA1A, NR1I3, OPRD1, OPRK1, OPRM1, POMC6
DB00844NalbuphineSmall MoleculeOPRD1, OPRK1, OPRM13
DB00854LevorphanolSmall MoleculeOPRD1, OPRK1, OPRM13
DB00899RemifentanilSmall MoleculeOPRD1, OPRK1, OPRM13
DB00921BuprenorphineSmall MoleculeOPRD1, OPRK1, OPRL1, OPRM14
DB01183NaloxoneSmall MoleculeCES1, CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR47
DB01209DezocineSmall MoleculeOPRK1, OPRM12
DB01221KetamineSmall MoleculeBCHE, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, GRIN3A, HTR1A, HTR1 ......23
DB014393-MethylthiofentanylSmall MoleculeOPRD1, OPRK1, OPRM13
DB01452HeroinSmall MoleculeCES1, OPRD1, OPRK1, OPRM14
DB01497EtorphineSmall MoleculeOPRD1, OPRK1, OPRL1, OPRM1, POMC, TRIM136
DB01535CarfentanilSmall MoleculeOPRD1, OPRK1, OPRM13
DB01548DiprenorphineSmall MoleculeOPRD1, OPRK1, OPRM1, TRIM134
DB01565DihydromorphineSmall MoleculeOPRD1, OPRK1, OPRM1, POMC, TRIM135
DB015713-MethylfentanylSmall MoleculeOPRD1, OPRK1, OPRM13
DB05046V1003Small MoleculeOPRK1, OPRM12
DB05104AsimadolineSmall MoleculeOPRK11
DB05155CR665Small MoleculeOPRK11
DB05443ADL 10-0101Small MoleculeOPRK11
DB06148MianserinSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, ......23
DB06204TapentadolSmall MoleculeHTR3A, OPRD1, OPRK1, OPRM1, SLC6A2, SLC6A46
DB06230NalmefeneSmall MoleculeOPRD1, OPRK1, OPRM13
DB06274AlvimopanSmall MoleculeOPRD1, OPRK1, OPRM13
DB06738KetobemidoneSmall MoleculeGRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, OPRD1, OPRK ......10
DB06800MethylnaltrexoneSmall MoleculeOPRK1, OPRM12
DB09209PholcodineSmall MoleculeOPRD1, OPRK1, OPRM13
DB09272EluxadolineSmall MoleculeOPRD1, OPRK1, OPRM13
DB09396Propoxyphene napsylateSmall MoleculeOPRD1, OPRK1, OPRM13
DB11130OpiumSmall MoleculeOPRD1, OPRK1, OPRM13
DB11691NaldemedineSmall MoleculeOPRD1, OPRK1, OPRM13